Overlooked Issues on Pharmacokinetics Data Interpretation of Protein Drugs-a Case Example of Erythropoietin.
作者信息
An Guohua, Schmidt Robert L, Mock Donald M, Veng-Pedersen Peter, Widness John A
机构信息
Division of Pharmaceutics and Translational Therapeutics, College of Pharmacy, University of Iowa, S227 Phar, 115 S. Grand Ave., Iowa City, Iowa, 52242, USA.
Department of Pediatrics, Roy J. and Lucille A. Carver College of Medicine, University of Iowa, Iowa City, USA.
出版信息
AAPS J. 2018 Nov 26;21(1):6. doi: 10.1208/s12248-018-0269-7.
Abstract
摘要
相似文献
1
Overlooked Issues on Pharmacokinetics Data Interpretation of Protein Drugs-a Case Example of Erythropoietin.
AAPS J. 2018 Nov 26;21(1):6. doi: 10.1208/s12248-018-0269-7.
2
An overview of the pharmacokinetic disposition of darbepoetin alfa.
Pharmacotherapy. 2002 Sep;22(9 Pt 2):133S-140S. doi: 10.1592/phco.22.14.133s.33396.
3
Control-relevant erythropoiesis modeling in end-stage renal disease.
IEEE Trans Biomed Eng. 2014 Mar;61(3):658-64. doi: 10.1109/TBME.2013.2286100. Epub 2013 Oct 16.
4
Erythropoietin stimulating agents and epoetin alfa revisited: what's really relevant?
Clin J Am Soc Nephrol. 2008 Jul;3(4):935-7. doi: 10.2215/CJN.02300508. Epub 2008 Jun 25.
5
[Current issues in erythropoietin therapy of renal anemia].
Lege Artis Med. 2007 Oct;17(10):667-73.
6
Population pharmacokinetics meta-analysis of recombinant human erythropoietin in healthy subjects.
Clin Pharmacokinet. 2007;46(2):159-73. doi: 10.2165/00003088-200746020-00004.
7
Pharmacokinetics and pharmacodynamics of epoetin alfa once weekly and three times weekly.
Eur J Clin Pharmacol. 2001 Aug;57(5):411-8. doi: 10.1007/s002280100324.
8
Efficacy estimation of erythropoiesis-stimulating agents using erythropoietin-deficient anemic mice.
Haematologica. 2016 Sep;101(9):e356-60. doi: 10.3324/haematol.2015.140814. Epub 2016 May 31.
9
How can erythropoeitin-stimulating agent use be reduced in chronic dialysis patients?: Adjuvant therapies to reduce erythropoiesis-stimulating agent dose requirements.
Semin Dial. 2013 Sep-Oct;26(5):543-5. doi: 10.1111/sdi.12108. Epub 2013 Jun 14.
10
Hyperhydration Effect on Pharmacokinetic Parameters and Detection Sensitivity of Recombinant Human Erythropoietin in Urine and Serum Doping Control Analysis of Males.
J Pharm Sci. 2019 Jun;108(6):2162-2172. doi: 10.1016/j.xphs.2019.01.017. Epub 2019 Jan 23.
引用本文的文献
1
Target-mediated disposition population pharmacokinetics model of erythropoietin in premature neonates following multiple intravenous and subcutaneous dosing regimens.
Eur J Pharm Sci. 2019 Oct 1;138:105013. doi: 10.1016/j.ejps.2019.105013. Epub 2019 Jul 21.
本文引用的文献
1
Bioanalytical approaches to quantify "total" and "free" therapeutic antibodies and their targets: technical challenges and PK/PD applications over the course of drug development.
AAPS J. 2011 Mar;13(1):99-110. doi: 10.1208/s12248-011-9251-3. Epub 2011 Jan 15.
2
Erythropoietin and erythropoiesis.
Exp Hematol. 2009 Sep;37(9):1007-15. doi: 10.1016/j.exphem.2009.05.010. Epub 2009 Jun 21.
3
Efficacy of recombinant erythropoietins: is there unity of international units?
Nephrol Dial Transplant. 2009 May;24(5):1366-8. doi: 10.1093/ndt/gfp058. Epub 2009 Feb 18.
4
Change in erythropoietin pharmacokinetics following hematopoietic transplantation.
Clin Pharmacol Ther. 2007 Jun;81(6):873-9. doi: 10.1038/sj.clpt.6100165. Epub 2007 Apr 11.
5
Erythropoietin pharmacokinetics in premature infants: developmental, nonlinearity, and treatment effects.
J Appl Physiol (1985). 1996 Jan;80(1):140-8. doi: 10.1152/jappl.1996.80.1.140.
6
The International Standard for Recombinant DNA-derived Erythropoietin: collaborative study of four recombinant DNA-derived erythropoietins and two highly purified human urinary erythropoietins.
J Endocrinol. 1992 Sep;134(3):459-84. doi: 10.1677/joe.0.1340459.
7
A sensitive and specific erythropoietin immunoprecipitation assay: application to pharmacokinetic studies.
J Lab Clin Med. 1992 Mar;119(3):285-94.
Zotero 插件